Recent Blog Articles
5 inflammation-fighting food swaps
Is IBD an underrecognized health problem in minority groups?
Sickle cell disease in newborns and children: What families should know and do
COVID-19 vaccines for children and teens: What we do — and don’t — know
Happy trails: Take a hike, now
Sleep well — and reduce your risk of dementia and death
COVID-19 vaccines and the LGBTQ+ community
Polycystic ovary syndrome and the skin
Dental appliances for sleep apnea: Do they work?
Terrified of needles? That can affect your health
Slow adoption of helpful heart failure drug
Many people who could benefit from spironolactone aren’t getting it.
In 1999, a large clinical trial showed that a drug called spironolactone (spih-row-noe-LACK-tone) could improve symptoms and lengthen life in some people with heart failure. More than 10 years later, only a minority of those who could benefit from the drug are taking it, even though it is inexpensive and guidelines for treating heart failure recommend its use.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.Sign Me Up
Already a member? Login ».
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.